Calidi Biotherapeutics, Inc.
New York Stock Exchange AmericanTotal Valuation
Calidi Biotherapeutics, Inc. carries a market capitalization of 1.22M, placing it among publicly traded companies globally. Its enterprise value stands at -2.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.22M |
| Enterprise Value | -2.93M |
Share Statistics
Calidi Biotherapeutics, Inc. currently has 11.79M shares outstanding.
| Shares Outstanding | 11.79M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.29 |
| P/FCF Ratio | -0.08 |
| P/OCF Ratio | -0.08 |
Financial Position
Calidi Biotherapeutics, Inc. maintains a current ratio of 1.92, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 45.73, indicating elevated leverage, while an interest coverage ratio of -102.21 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.92 |
| Quick Ratio | 1.73 |
| Debt / Equity | 45.73 |
| Debt / EBITDA | -0.13 |
| Interest Coverage | -102.21 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -154.35 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 16,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Calidi Biotherapeutics, Inc.'s stock has declined approximately -96.13084% over the past 52 weeks. The 50-day moving average sits at 0.23, while the 200-day moving average is 1.04.
| Beta (5Y) | N/A |
| 52-Week Price Change | -96.13084% |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | 1.04 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -17.68M, while operating income came in at -19.36M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -19.36M |
| Pretax Income | -19.09M |
| Net Income | -19.03M |
| EBITDA | -17.68M |
| EBIT | -19.36M |
| Earnings Per Share (EPS) | -3.17 |
Balance Sheet
Calidi Biotherapeutics, Inc. holds 6.63M in cash and equivalents against 2.26M in total debt, resulting in a net debt position of -6.03M. Total book value stands at -145.73M, with working capital of 3.52M providing operational flexibility.
| Cash & Cash Equivalents | 6.63M |
| Total Debt | 2.26M |
| Net Debt | -6.03M |
| Equity (Book Value) | -145.73M |
| Book Value Per Share | -24.16 |
| Working Capital | 3.52M |
Cash Flow
Calidi Biotherapeutics, Inc. produced -18.28M in operating cash flow over the past twelve months. After subtracting -118,000.00 in capital expenditures, free cash flow totaled -18.40M - equivalent to -3.05 per share.
| Operating Cash Flow | -18.28M |
| Capital Expenditures | -118,000.00 |
| Free Cash Flow | -18.40M |
| FCF Per Share | -3.05 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1,007.55 |
| FCF Yield | -1,261.00 |
Stock Splits
Calidi Biotherapeutics, Inc.'s most recent stock split took place on August 5, 2025 with a 12:1 split ratio.
| Last Split Date | 8/5/2025 |
| Split Ratio | 12:1 |
Scores
Calidi Biotherapeutics, Inc. posts an Altman Z-Score of -27.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -27.31 |